O-Glycosylation Regulates Ubiquitination and Degradation of the Anti-Inflammatory Protein A20 to Accelerate Atherosclerosis in Diabetic ApoE-Null Mice by Shrikhande, Gautam V. et al.
O-Glycosylation Regulates Ubiquitination and
Degradation of the Anti-Inflammatory Protein A20 to
Accelerate Atherosclerosis in Diabetic ApoE-Null Mice
Gautam V. Shrikhande
1¤a, Salvatore T. Scali
1¤b, Cleide G. da Silva
1, Scott M. Damrauer
1, Eva Csizmadia
1,
Prabhakar Putheti
2, Michaela Matthey
1, Roy Arjoon
1, Rakesh Patel
1, Jeffrey J. Siracuse
1, Elizabeth R.
Maccariello
1¤c, Nicholas D. Andersen
1¤d, Thomas Monahan
1, Clayton Peterson
1, Sanah Essayagh
1, Peter
Studer
1, Renata Padilha Guedes
1, Olivier Kocher
3, Anny Usheva
4, Aristidis Veves
5, Elzbieta Kaczmarek
1,
Christiane Ferran
1,6,7*
1The Division of Vascular Surgery, Department of Surgery and the Center for Vascular Biology Research, Department of Medicine, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, Massachusetts, United States of America, 2The Transplant Institute, Department of Medicine, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, Massachusetts, United States of America, 3The Department of Pathology, Department of Medicine, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, Massachusetts, United States of America, 4The Division of Endocrinology, Department of Medicine, Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, Massachusetts, United States of America, 5Joslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, Department
of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, 6The Transplant Institute, Department of
Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, 7Division of Nephrology, Department of
Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
Abstract
Background: Accelerated atherosclerosis is the leading cause of morbidity and mortality in diabetic patients. Hyperglycemia
is a recognized independent risk factor for heightened atherogenesis in diabetes mellitus (DM). However, our
understanding of the mechanisms underlying glucose damage to the vasculature remains incomplete.
Methodology/Principal Findings: High glucose and hyperglycemia reduced upregulation of the NF-kB inhibitory and
atheroprotective protein A20 in human coronary endothelial (EC) and smooth muscle cell (SMC) cultures challenged with
Tumor Necrosis Factor alpha (TNF), aortae of diabetic mice following Lipopolysaccharide (LPS) injection used as an
inflammatory insult and in failed vein-grafts of diabetic patients. Decreased vascular expression of A20 did not relate to
defective transcription, as A20 mRNA levels were similar or even higher in EC/SMC cultured in high glucose, in vessels of
diabetic C57BL/6 and FBV/N mice, and in failed vein grafts of diabetic patients, when compared to controls. Rather,
decreased A20 expression correlated with post-translational O-Glucosamine-N-Acetylation (O-GlcNAcylation) and
ubiquitination of A20, targeting it for proteasomal degradation. Restoring A20 levels by inhibiting O-GlcNAcylation,
blocking proteasome activity, or overexpressing A20, blocked upregulation of the receptor for advanced glycation end-
products (RAGE) and phosphorylation of PKCbII, two prime atherogenic signals triggered by high glucose in EC/SMC. A20
gene transfer to the aortic arch of diabetic ApoE null mice that develop accelerated atherosclerosis, attenuated vascular
expression of RAGE and phospho-PKCbII, significantly reducing atherosclerosis.
Conclusions: High glucose/hyperglycemia regulate vascular A20 expression via O-GlcNAcylation-dependent ubiquitination
and proteasomal degradation. This could be key to the pathogenesis of accelerated atherosclerosis in diabetes.
Citation: Shrikhande GV, Scali ST, da Silva CG, Damrauer SM, Csizmadia E, et al. (2010) O-Glycosylation Regulates Ubiquitination and Degradation of the Anti-
Inflammatory Protein A20 to Accelerate Atherosclerosis in Diabetic ApoE-Null Mice. PLoS ONE 5(12): e14240. doi:10.1371/journal.pone.0014240
Editor: Gian Paolo Fadini, University of Padova, Italy
Received June 4, 2010; Accepted October 14, 2010; Published December 6, 2010
Copyright:  2010 Shrikhande et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by National Institutes of Health (NIH) Research Project Grant Program (R01) grants HL080130, RO1 DK063275, and
HL057791; Juvenile Diabetes Research Foundation grant 1-2007-567 to CF; NIH R01 grant HL075678; an American Diabetes Association clinical research grant to
AV; and NIH RO1 grant HL062458 to AU. GVS, STS, SMD, VIP, JSJ, CP and MDF are recipients of a fellowship award from the NIH T32 fellowship grant HL07734. PS is
the recipient of a fellowship grant from the Swiss National foundation. RPG is the recipient of a research fellowship grant from the CNPQ, Brasil. The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cferran@bidmc.harvard.edu
¤a Current address: Division of Vascular Surgery, Columbia University Medical Center, New York, New York, United States of America
¤b Current address: Division of Vascular Surgery, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States of America
¤c Current address: University Federal of Rio de Janeiro, Brazil
¤d Current address: Duke University Medical Center, Durham, North Carolina, United States of America
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14240Introduction
Diabetic macrovasculopathy (DV), an accelerated form of
atherosclerosis, is the leading cause of morbidity and mortality
in diabetes mellitus (DM). Diabetic patients suffer a 2 to 4-fold
increase in the incidence of coronary artery disease and stroke and
a .10-fold increase in the incidence of peripheral vascular disease
[1]. This begs for a better understanding of the molecular basis for
DV.
Multiple risk factors including insulin resistance, dyslipidemia,
and hyperglycemia account for accelerated atherosclerosis in
patients suffering from type II diabetes mellitus [2]. On the cellular
level, endothelial (EC) and smooth muscle (SMC) cells accumulate
intracellular glucose during hyperglycemic episodes [3,4]. This
leads to the generation of reactive oxygen species (ROS) by the
mitochondrial electron transport chain [5], setting in motion a
number of pro-atherogenic signals that culminate in the
phosphorylation of PKCbII [6], generation of advanced glycation
end-products (AGE) [7], and amplification of inflammatory
responses through activation of NF-kB [5]. All of these processes
contribute to vascular complications of diabetes [8]. Additionally,
high glucose enhances glucose flux through the hexosamine
biosynthetic pathway (HBP), increasing the conversion of glucose
to UDP-N Acetylglucosamine (UDP-GlcNAc), the substrate
required for protein O-GlcNAcylation [9]. O-GlcNAcylation acts
as a glucose sensor in that it is a dynamic, reversible post-
translational modification (PTM) that responds to extra-cellular
stimuli [10,11]. In the vasculature, O-GlcNAcylation tips the
balance towards heightened atherogenesis by decreasing the
function of atheroprotective proteins, such as endothelial nitric
oxide synthase (eNOS), while increasing the transcription of pro-
atherogenic genes, such as thrombospondin-1 [12,13,14,15].
A20 maps to an atherosclerosis susceptibility locus in mice, with
a single point mutation resulting in diminished A20 function in
atherosclerosis-prone C57BL/6 mice as compared to atheroscle-
rosis-resistant FBV/N [16,17]. Our group demonstrated that A20
plays a crucial role in preventing and reverting neointimal
hyperplasia through its effects in both EC and SMC [18]. A20
protects EC from apoptosis and blocks inflammation by inhibiting
NF-kB activation in response to a broad spectrum of pro-
atherogenic activators [19,20,21]. On the molecular level, The
NF-kB inhibitory function of A20 is supported by its ubiquitin-
editing functions [22]. A20 exerts dual deubiquitinase and
ubiquitin ligase enzymatic activities that target adaptor and
signaling molecules such as receptor interacting protein (RIP)
and TNF-R associated protein (TRAF-6) either promoting their
proteasomal degradation or regulating their interactions with
other signaling molecules. In fact, A20 is part of an ubiquitin-
editing protein complex, which includes Ring domain protein
(RNF11) and the regulatory molecule TAX1BP1, which is
implicated in the disruption of ubiquitin enzyme complexes
through ubiquitination and degradation of the E2 ubiquitin
conjugating enzymes Ubc13 and UbcH5c [23,24]. Importantly,
A20 maintains its anti-inflammatory/NF-kB inhibitory function in
SMC, blocking upregulation of the pro-atherogenic proteins inter
cellular adhesion molecule (ICAM-1) and monocyte chemoat-
tractant protein-1 (MCP-1) and inhibiting SMC proliferation [18].
Additionally, A20 sensitizes intimal SMC to apoptosis through a
NO-dependent mechanism, promoting regression of established
lesions of intimal hyperplasia [18]. In this work, we questioned
whether glucose alters the expression/function of A20 in EC and
SMC, and whether this impacts the incidence/progression of DV
in a mouse model [19,25]. Our results indicate that A20 undergoes
specific glucose-triggered post-translational modifications (PTM)
including O-GlcNAcylation and ubiquitination, which leads to its
loss by proteasomal degradation, hence depriving the organism of
a key element of its atheroprotective armamentarium and
accelerating development of atherosclerotic lesions.
Results
High glucose decreases A20 protein levels in response to
inflammatory stimuli in SMC and EC without affecting
mRNA levels
To evaluate the impact of high glucose on expression of the
atheroprotective protein A20, we cultured SMC in physiologic
(5 mM) and high (30 mM) D-Glucose (D-Glu), or the respective
osmotic controls [25 mM of L-Glucose (L-Glu) or mannitol in
addition to the 5 mM D-Glu present in the medium] for 24 h,
challenged them with TNF at 200 U/ml, recovered cell extracts
6 h later, and checked for A20 expression by Western blot analysis
(WB). In preliminary experiments, we had determined that A20
protein levels peaked 6 h following TNF stimulation in both EC
and SMC. In SMC cultured in 5 mM D-Glu or the osmotic
controls (L-Glu or Mannitol), we consistently noted 1.5 to 2.0-fold
increase in A20 protein levels 6 h following TNF treatment. TNF-
mediated upregulation of A20 decreased, by at least 30%–35%, in
SMC cultured in 30 mM D-Glu (Figure 1A). In contrast to A20
protein, A20 mRNA significantly increased within 1 h following
TNF addition and remained increased at 3 h regardless of the
culture medium used, indicating that high glucose did not impact
A20 transcription or mRNA stability (Figure 1B). In preliminary
experiments, we had determined that A20 mRNA levels peaked
1–3 h following TNF stimulation in EC and SMC. Similar results
were obtained in EC. We consistently noted a 2.5 to 3.7-fold
increase in A20 protein levels 6 h following TNF treatment in EC
cultured in 5 mM D-Glu and the osmotic controls. TNF-mediated
upregulation of A20 also decreased by 30% in EC cultured in high
glucose (15 and 30 mM D-Glu; Figure 2A), while TNF-mediated
upregulation of A20 mRNA was not affected (Figure 2B).
Hyperglycemia blunts the physiologic increase of A20
protein in the mouse vasculature following an
inflammatory insult and in failed vein grafts of diabetic
patients
To check whether hyperglycemia attenuates vascular upregula-
tion of A20 in response to an inflammatory insult, and validate our
in vitro results, we challenged diabetic and non-diabetic C57BL/6
and FVB/N mice with LPS. These mice strains were chosen
because of their described resistance and susceptibility, respec-
tively, to atherosclerosis, based on the function and expression
levels of their A20 gene. Indeed, a single point mutation in the
C57BL/6 A20 gene decreases its ability to inhibit NF-kB
activation, and hence to temper inflammation, rendering these
mice susceptible to atherosclerosis. FVB/N mice express a non-
mutated form of A20 that exerts a greater NF-kB inhibitory and
anti-inflammatory effect, protecting them from atherosclerosis
[16,17]. LPS injection increased A20 protein levels by 2- to 3-fold
in aortae of non-diabetic C57BL/6 and FVB/N mice. In contrast,
we did not detect any A20 protein in the aortae of LPS-treated
diabetic mice despite higher A20 mRNA levels in aortae of
diabetic, LPS-treated mice, whether C57BL/6 or FVB/N,
compared to non-diabetic mice (Figure 3A & B). These data
imply that hyperglycemia decreases A20 expression through
translational or post-translational mechanisms independently from
transcriptional regulation and genetic polymorphism. As a result
both the ‘‘functional’’ i.e. atheroprotective A20 protein of FVB/N
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equally lost [16].
These data are supported by our clinical observation that almost
no A20 protein was detected in failed vein grafts of diabetic
patients despite significantly higher A20 mRNA levels in these
veins (5.5 to 7.2-fold more). This finding reflects the heightened
inflammation that is known to be associated with diabetes, as
compared to A20 mRNA levels detected in failed vein grafts from
patients suffering from pro-inflammatory and pro-atherogenic
conditions other than diabetes (Figure 4A&B). In contrast, A20
protein levels were higher in failed vein grafts from non-diabetic
patients (as expected in response to ongoing inflammation within
these failed vein grafts) (Figure 4A, n=4 patients per group),
despite lower A20 mRNA levels in these veins, as compared to
A20 mRNA levels in the failed veins recovered from diabetic
patients (Figure 4B, samples paired with WB & Figure 4C, n=6
patients per group). Although the pathophysiology of failed vein
grafts is different from that of atherosclerosis, this data allowed us
to clinically confirm the discrepancy between high A20 mRNA
levels and low A20 protein levels in the vasculature of diabetic
versus non-diabetic patients.
A20 is O-GlcNAcylated and ubiquitinated in SMC cultured
in high glucose
We searched for glucose-induced PTM that could account for
decreased A20 protein levels in cells exposed to high glucose and
TNF, focusing on SMC cultures since they are the principal cell
type comprising atherosclerotic lesions. Most of these experiments
were reproduced at least once in EC. A20 does not contain any N-
glycosylation consensus motif [26]. However, we identified several
Figure 1. Increasing glucose (D-Glu) concentrations decreases
TNF-mediated A20 protein up-regulation without affecting its
transcriptional activation in SMC. (A) Analysis of A20 expression by
WB. SMC were cultured in 5, or 30 mM D-Glu, or the osmotic control
(25 mM L-Glu +5 mM D-Glu), and treated with TNF for 6 h. bactin was
checked as a loading control and used to quantify relative A20
expression by densitometry, as reported beneath the WB. Densitometry
of the bands of interest and was determined as the mean intensity of
the areas delineated by Image J, then corrected by the main intensity of
the corresponding housekeeping gene band. Fold induction was
determined using the non-treated 5 mM D-glucose condition sample
as one (1). Data are representative of 3 independent experiments. The
cuts between samples reflect the fact that these samples, while on the
same gel and same experiment, were not contiguous. (B) Analysis of
A20 mRNA levels by real-time PCR. SMC were cultured in 5 or 30 mM D-
Glu or mannitol (25 mM Mannitol +5 mM D-GLu), as an osmotic control,
and treated with TNF for 1 or 3 h. 18S ribosomal RNA was used to
normalize the data. Natural log transformed data (ln) are presented as
mean6SEM of 3 independent experiments performed in duplicate. No
significant differences (P.0.05) were noted between all groups and at
all time-points.
doi:10.1371/journal.pone.0014240.g001
Figure 2. Increasing glucose (D-Glu) concentrations decreases
TNF-mediated A20 protein up-regulation without affecting its
transcriptional activation in EC. (A) Analysis of A20 expression by
WB. EC cultured in medium containing 5, 15 or 30 mM D-glucose (D-
Glu) or L-glucose (L-Glu), as an osmotic control, were stimulated with
TNF for 6 h ˜bactin was checked as loading control and to quantify
relative A20 expression by densitometry, as reported below the WB.
Densitometry of the bands of interest and was determined as the mean
intensity of the areas delineated by Image J, then corrected by the main
intensity of the corresponding house keeping gene band. Fold
induction was determined using the non-treated 5 mM D-glucose
condition sample as one (1). A20 protein migrates as a doublet in EC
and hence both bands were scanned. Data are representative of 3
independent experiments. (B) Analysis of A20 mRNA levels by real-time
PCR. EC cultured in medium containing 5, 15 or 30 mM D-Glu or L-Glu
as an osmotic control, were stimulated with TNF for 1 and 3 h.
Expression of 18S ribosomal RNA was used to normalize the expression
of A20 mRNA. Natural log transformed data (ln) are presented as
mean6SEM of 3 independent experiments performed in duplicate. No
significant differences (P.0.05) were observed between all groups and
at all time-points.
doi:10.1371/journal.pone.0014240.g002
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GlcNAcylated [27]. Immunoblots using the anti-GlcNAc anti-
body, RL-2, demonstrated a 90-kDa band that overlapped with
the band recognized by the anti-A20 antibody in lysates from
SMC cultured in 5, 15 and 30 mM D-Glu and treated with TNF
for 6 h. This suggested that A20 undergoes modification by O-
linked N-Acetylglucosamine under conditions of high glucose
(Figure 5A). While TNF-mediated upregulation of total A20
protein decreased in SMC cultured in 15 and 30 mM D-Glu, O-
GlcNAcylation of the 90 kDa A20 band, detected in a co-
immunoblot using an RL-2 antibody, increased in parallel with
increasing glucose concentrations, as determined by RL-2/A20
densitometry ratios. To confirm that A20 was targeted for post-
translation O-GlcNAcylation, and given the difficulty of perform-
ing immunoprecipitation with the currently available anti-GlcNAc
antibodies, namely RL-2, we first mixed cell lysates from TNF-
treated SMC cultured in 5 or 30 mM D-Glu with wheat germ
agglutinin (WGA) affinity beads. The WGA lectin preferentially
binds terminal N-acetyl glucosamine (GlcNAc) structures i.e. both
N-linked Asparagine and O-linked serine/threonine residues, but
also has high affinity for sialic acid [28]. WB analysis of WGA
captured proteins using rabbit anti-A20 polyclonal antibody
showed that A20 was one of the WGA-captured proteins
(Figure 5B). Since WGA columns are relatively non-specific, the
same cell lysates were also immunoprecipitated (IP) with the rabbit
anti-A20 antibody (IP-A20). WB of IP-A20 samples with anti-A20
and RL-2 antibodies indicated that A20 was O-GlcNAcylated in
both 5 and 30 mM D-Glu, albeit at a greater ratio in cells cultured
in HG. The ratio of GlcNAc-A20 over total A20 (determined by
densitometry) increased by 1.4 to 2 fold in SMC cultured in
30 mM D-Glu (Figure 5C).
To determine whether increased O-GlcNAc of A20 contributed
to its decreased protein levels, we probed for accelerated
degradation of GlcNAcA20 by the ubiquitin/proteasome path-
way. Using WB with an anti-ubiquitin antibody, we identified a
faint positive band migrating at 90 kDa (likely Ub-A20) that was
detected in WGA-captured proteins from TNF-treated SMC,
cultured in 30 mM D-Glu (Figure 5B). To further explore this
observation, we immunoprecipated cell lysates from TNF-treated
SMC cultured in 5 and 30 mM D-Glu with the rabbit anti-A20
polyclonal antibody. WB of IP-A20 samples, using anti-ubiquitin
and anti-A20 antibodies demonstrated that high glucose increased
Figure 3. LPS-mediated upregulation of A20 protein expression is blunted in aortae of diabetic, as compared to non-diabetic mice.
(A) WB of A20 in abdominal aortae of diabetic and non-diabetic atherosclerosis-prone C57BL/6 and atherosclerosis-resistant FVB/N mice, 8 h after LPS
treatment. GAPDH and bactin were used to correct for loading and quantify relative A20 expression by densitometry, as reported below the WB. Data
shown are representative of 3 (non-diabetic) and 4 (diabetic) mice per time-point and illustrate the loss of LPS-induced A20 protein in diabetic mice,
regardless of strain. The cuts between samples reflect the fact that these samples, while on the same gel and same experiment, were not contiguous.
(B) A20 mRNA levels analyzed by real-time PCR 3 to 8 h after LPS injection in mouse abdominal aortae (n=5 non-diabetic and 7 diabetic mice in
C57BL/6 and 3 non-diabetic and 4 diabetic mice in FVB/N). Data shown demonstrates that LPS increases A20 mRNA levels in aortae of diabetic and
non-diabetic C57BL/6 and FVB/N, albeit at a greater levels in diabetic mice. Expression of 18S ribosomal RNA was used to normalize expression of A20
mRNA, and the results were presented as mean6SEM of mRNA. Each sample was measured in duplicate.
doi:10.1371/journal.pone.0014240.g003
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to 2.5-fold before and 6 h after treatment with TNF (Figure 5D).
Notably, data shown in Figure 5C & 5D demonstrate remarkable
similarity between GlcNAc-A20/total-A20 and Ub-A20/total-A20
ratios, suggesting that these PTM could be interdependent.
To that effect, inhibiting glutamine fructose-6 phosphate
amidotransferase (GFAT), which catalyzes the first and rate-
limiting step in the formation of glucosamine and hexosamine
products[29], by pre-treating SMC cultured in 30 mM D-Glu
with its specific inhibitor 6-diazo-5-oxo-norleucine (DON, 50 mM)
1 h prior to TNF treatment, or addition of the proteasome
inhibitor MG132 (10 mM) 1 h following TNF treatment, restored
A20 protein expression (Figure 5E). WB using RL-2 confirmed
that pre-treatment with DON inhibited A20 O-GlcNAcylation,
while treatment with MG132 allowed for the accumulation of an
O-GlcNAcylated A20. Similar results were obtained when using
another GFAT inhibitor, Azaserine (20 mM) (Figure 6A).
Since A20 function is, at least in part, regulated by
phosphorylation of Ser381 [30], we investigated whether high
glucose affects TNF-induced phosphorylation of A20 in SMC by
WB analysis using specific anti-phospho A20 antibody. High
glucose had no effect on TNF-mediated A20 phosphorylation, as it
did not decrease the ratio of phosphorylated to total A20 levels
(Figure 5F). Similar results were obtained in EC (data not shown).
Inhibition of proteasome activity or overexpression of
A20 inhibits high glucose-mediated upregulation of
RAGE and phosphorylation of PKCbII
AGE/RAGE signaling is one of the key pathways implicated in
the pathophysiology of DV [31,32]. We confirmed by WB that
RAGE levels increased in SMC cultured in 30 mM D-Glu and
that this increase was further amplified by TNF (Figure 6A).
Restoring A20 protein by inhibiting O-GlcNAcylation (with
Azaserine), or blocking the activity of the proteasome (with
MG132) significantly inhibited upregulation of RAGE by high
glucose and TNF (Figure 6A). Similar results were obtained when
A20 protein levels were restored by transducing SMC with
rAd.A20 (Figure 6B). This indicates that considerable overexpres-
sion of A20 overwhelms the glycosylation/ubiquitination machin-
ery, maintaining adequate levels of functional A20, as gauged by
its ability to decrease RAGE upregulation.
Activation of PKCbII in response to high glucose is another
pathwayinvolvedinpromotingDV[6].ByWB,wedetermined that
PKCbII was phosphorylated, and thus activated in non-transduced
(NT) and rAd.bgal-transduced SMC challenged for 1 h with
30 mM D-Glu, similarly to what we observed upon treatment with
1 mM phorbol 12-myristate 13-acetate (PMA). High glucose and
PMA-mediated phosphorylation of PKCbII was inhibited or even
abolished in A20-overexpressing SMC (Figure 6C).
Expression of A20 in aortic arches protects diabetic
ApoE-null mice from accelerated atherosclerosis
As stated earlier, diabetes accelerates and aggravates atheroscle-
rosisinApoE-null mice[33]. Havingdemonstratedthatdiabetic mice
express lower A20 levels under inflammatory conditions, we
questioned whether restoring A20 levels in the vasculature could
prevent accelerated atherosclerosis in diabetic ApoE-null mice. We
overexpressed A20 in aortic arches of diabetic ApoE-null mice six
weeks after documentation of diabetes( e a r l ys t a g e so fa t h e r o s c l e r o t i c
lesion development) by administering rAd.A20 (5610
9 pfu) through
the left ventricle. This route of adenovirus delivery leads to
preferential expression of the transgene in medial SMC and the
adventitia, peaking at 5 days following administration, as shown by
Figure 4. Lower A20 protein levels contrast with increased
mRNA levels in failed vein grafts of diabetic patients. (A) A20
protein expression and (B) mRNA levels (real-time PCR, lower panel) in
failed vein grafts recovered from non-diabetic (ND) and patients with
type I and type II DM (t1 and t2 DM) show lower A20 protein levels in
failed vein grafts of diabetic patients as compared to non-diabetic
patients, despite significantly higher A20 mRNA levels in these samples.
Expression of GAPDH was checked as a loading control and to quantify
relative A20 expression by densitometry. A20/GAPDH ratios are listed
below the WB. Data shown are representative of 4 patients in each
group. Samples were all run on the same gel but are shown as separate
because they were not loaded contiguously. (B) A20 mRNA levels of the
same failed vein grafts shown in 4A demonstrate increased A20 mRNA
levels in failed vein grafts from diabetic vs. non-diabetic patients. 18S
ribosomal RNA was used to normalize the data. Data is expressed as
fold increase of A20 mRNA using the A20 mRNA level detected in the
failed vein graft of the non-diabetic patient as a baseline value. (C) A20
mRNA levels analyzed by real time PCR from failed vein grafts of
diabetic (DM) and non-diabetic (ND) patients show significantly higher
A20 mRNA in failed vein grafts of diabetic versus non-diabetic patients;
**p=0.0016. 18S ribosomal RNA was used to normalize the data.
Natural log transformed data (ln) are presented as mean6SEM of 6
failed vein grafts per group. The 6 failed vein grafts from diabetic
patients included 2 type I and 4 type II DM patients. Data is expressed
as fold increase of A20 mRNA using the A20 mRNA level detected in the
failed vein graft of the non-diabetic patient shown in Figure 1A, as a
baseline value.
doi:10.1371/journal.pone.0014240.g004
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confirmed A20 overexpression in aortic arches of mice treated with
rAd.A20 by real-time PCR (Figure 7B). We sacrificed mice at 20
weeks and recovered their aortic arches for evaluation. Ten serial
sections 50 mm apart were evaluated per vessel. There were
prominent atherosclerotic lesions in saline and rAd.bgal-treated
vessels showing significant expansion of the intima, foam cell
infiltration and reduction of the media. I/M ratios reached
0.4260.08 and 0.7760.17, respectively (Figure 7C). A20 expression
significantly inhibited the development of atherosclerotic lesions with
calculated I/M ratios reaching 0.2160.04 (P=0.024 vs. saline and
P=0.006 vs. rAd.bgal) (Figure 7C). The protective effect of A20
againstDV did notcorrelate withan effect ofA20on blood glucoseor
cholesterol levels, which remained comparable among groups
(Figure 7B). As expected, hyperlipidemia was worsened by diabetes
(P,0.01; Figure 7C). Two control groups included non-diabetic
ApoE-null mice that showed fewer cellular lesions as well as C57BL/
6 mice that displayed normal vascular architecture. Importantly, the
protective effectof A20 againstDV required local vascular expression
of the transgene. Intravenous administration of rAd.A20 to diabetic
ApoE-null failed to protect from accelerated atherosclerosis, ruling
out a systemic effect of A20 on the observed outcome (Figure 8).
A20 protects against accelerated atherosclerosis of DM
by inhibiting PKCbII phosphorylation and attenuating
RAGE upregulation in vivo
By immunohistochemistry (IHC), we detected numerous EC
and intimal SMC as well as a few medial SMC that intensely
stained for phospho-PKCbII in mouse aortic atherosclerotic
Figure 5. O-GlcNAcylation and ubiquitination of A20 modulate its expression. (A) WB analysis of total A20 and co-immunoblotted,
overlapping GlcNAc-A20 (RL-2) in SMC cultured in 5, 15 and 30 mM of D-glucose (D-Glu), and treated or not with TNF for 6 h. b-actin was used as a
control for loading. (B) WB analysis of WGA captured proteins from SMC cultured in 5 and 30 mM D-Glu demonstrate the presence of glycosylated
(GlcNAcA20), and co-immunoblotted, overlapping, ubiquitinated A20 (Ub-A20). (C) WB analysis of cell lysates immunoprecipitated with the A20
antibody from SMC cultured in 5 and 30 mM of D-Glu and treated or not with TNF for 6 h, and analyzed WB for total A20 and GlcNAc-A20 using the
RL2 antibody demonstrate increased GlcNAc-A20 in high glucose medium. (D) WB analysis of cell lysates immunoprecipitated with the A20 antibody
from SMC cultured in 5 and 30 mM D-Glu and treated or not with TNF for 6 h, and analyzed by WB for total and Ub-A20 demonstrate increased Ub-
A20 in high glucose medium. (E) WB analysis of total and overlapping GlcNAc-A20 (RL-2) in SMC cultured in 30 mM D-Glu and treated with DON (prior
to TNF) or MG132 (after TNF). (F) WB analysis of total and phospho-A20 in SMC cultured in 5, 15 and 30 mM D-Glu and treated with TNF for 6 h
demonstrated that relative phosphorylation levels of A20 (pA20) were not decreased by high glucose, despite decreased TNF-mediated upregulation
of A20 protein in cells cultured in high glucose. GAPDH or bactin was checked as a loading control to quantify A20 expression by densitometry.
Corrected A20 fold-inductions are listed below the WB. RL2/A20 and Ubiquitin/A20 ratios were also calculated by densitometry. Data shown in A, C,
D, and E are representative of 3 independent experiments. Data shown in B and F are representative of 2 independent experiments.
doi:10.1371/journal.pone.0014240.g005
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pression of A20 in aortic arches decreased the intensity of
phospho-PKCbII immunostaining and limited its expression to
only a few EC (Figure 7D). Similar results were obtained 14 days
after gene transfer (data not shown). We did not detect phospho-
PKCbII positive cells in aortic arches of ApoE-competent C57BL/
6 mice and detected only faint immunostaining in organized
atherosclerotic lesions of non-diabetic ApoE-null mice.
There was significant RAGE expression in aortic atherosclerotic
lesions of diabetic Apo-E-null mice (EC and medial SMC) even
prior to transgene delivery (data not shown). RAGE immuno-
staining intensified and extended to developing neointimal SMC
and foam cells 14 days following saline and rAd.bgal administra-
tion (Figure 7D). In contrast, RAGE immunostaining was blunted
in A20-expressing aortic arches and was similar to staining
detected in non-diabetic C57BL/6 mice. We also identified RAGE
positive EC and neointimal SMC in atherosclerotic lesions of non-
diabetic ApoE-null mice, but the number of positive cells and
intensity of staining were lower in comparison to diabetic ApoE-
null mice. Intravenous administration of rAd.A20 did not affect
the intensity or distribution of phospho-PKCbII and RAGE
immunostaining in the atherosclerotic lesions of diabetic ApoE-
null mice, further indicating that the atheroprotective effect of A20
requires local vascular expression (Figure 8).
Discussion
Several studies have identified poor glycemic control and
heightened TNF levels as potential risk factors for vascular
complications in DM [34,35]. It seems well established that
standard glycemic control (hemoglobin A1C between 7 and 7.9%)
is beneficial for reducing micro and macrovascular complications
of diabetes [36]. However, the ACCORD study has clearly shown
that a very strict glycemic control (hemoglobin A1C levels lower
than 6%), while still beneficial for reducing the risk of diabetic
retinopathy, increases the incidence of fatal cardiovascular events
for reasons that are still poorly understood [37,38]. Accordingly,
we set our goals to define the molecular targets of high glucose in
EC and SMC that support increased atherosclerosis, and
determine ways that could rescue his phenotype, independently
from glycemic control. We demonstrated that hyperglycemia
amplifies the risk for atherosclerosis through decreased vascular
expression of the physiologic ‘‘atheroprotective’’ protein A20. A20
upregulation in response to inflammatory signals was greatly
reduced in EC and SMC cultured in high glucose, and in vessels of
hyperglycemic mice and patients. Decreased A20 levels in
response to high glucose did not result from transcriptional
repression. A20 mRNA levels were even greater in vessels of
hyperglycemic vs. non-hyperglycemic mice and patients, which is
consistent with the fact that NF-kB activation is amplified by high
glucose, increasing transcription of downstream NF-B-dependent
A20 [39]. Rather, high glucose decreased A20 expression at the
post-translational level by promoting its O-GlcNAcylation and
ubiquitination. We detected GlcNAc-A20 in cells cultured in
physiologic glucose concentrations, but its levels were amplified by
high glucose concentrations, likely as the result of increased flux
through the hexosamine biosynthetic pathway [40]. We also
demonstrated, in vitro, that O-GlcNAcylation and ubiquitination of
A20 increased in parallel, which suggested that these PTM could
be, related either directly or indirectly. Accordingly, A20 was
shunted away from proteasomal degradation when O-GlcNAcyla-
tion was inhibited, allowing recovery of A20 protein levels in the
face of high glucose and inflammation (mimicked by TNF).
Moreover, we restored sufficient A20 protein levels by inhibiting
the activity of the 26S proteasome, which led to the accumulation
of a functional GlcNAc/Ub A20, as demonstrated by decreased
expression of the NF-kB dependent pro-inflammatory gene,
RAGE, a direct target of the NF-kB inhibitory protein A20
[41]. Our result demonstrating that O-GlcNAcylation promotes
the ubiquitination of certain proteins agrees with work by Guinez
et al. It shows that conditions that promote protein O-
GlcNAcylation also enhance protein ubiquitination; conversely,
inhibiting O-GlcNAcylation reduces protein ubiquitination in
HepG2 cells [42]. Our data focusing on A20 in primary SMC
echoes their conclusion that O-GlcNAcylation regulates ubiquiti-
nation in a sequential and dependent manner. However, with A20
being a target for both PTM, our current data does not allow us to
distinguish whether O-GlcNAcylation of A20 is required or is
merely a marker for its subsequent ubiquitination. In the former
scenario, one may envision that O-GlcNAcylation of A20 could
modify the availability and/or function of its own ubiquitin ligase
domain to promote its autoubiquitination [22]. In the latter
scenario, A20 O-GlcNAcylation may be a simple indicator for O-
GlcNAcylation levels, targeting other ubiquitin editing enzymes
(i.e. ubiquitin activating enzyme E1) to increase their activity and
hence ubiquitination of their target proteins including, A20 [42].
Future work in the laboratory is aimed at clarifying this issue by
generating GlcNAc-resistant (once the identity of O-GlcNAcylated
residues in A20 are identified) and/or ubiquitin ligase deletion
A20 mutants.
Our data contrast, however, with other results suggesting that
promoting O-GlcNAcylation protects some proteins such as Sp1
from proteasomal degradation[43]. Sp1 protein stabilization in
Figure 6. Restoring A20 levels reverts glucose-mediated
upregulation of RAGE and phosphorylation of PKCbII. (A) WB
analysis for RAGE and A20 expression in SMC cultured in 5 or 30 mM D-
Glu for 24 h and treated with TNF in the presence or absence of 20 mM
of Azaserine (prior to TNF) or 10 mM of MG132 (following TNF).
Corrected RAGE fold-inductions are listed below the WB. The RAGE
protein is detected as a doublet as a result of pre and post-N-
glycosylated form of the protein. Both bands were used for
densitometry evaluation. (B) WB analysis of phospho-PKCbII (pPKCbII)
and total (c) PKCbII in NT SMC, and in SMC transduced with rAd.A20 or
rAd.bgal, and treated with PMA or challenged with 30 mM D-Glu for
1 h. Data shown in A and B are representative of 3 independent
experiments. NT=non-transduced cells. GAPDH was used as loading
control to quantify the relative expression of RAGE and pPKCbII by
densitometry.
doi:10.1371/journal.pone.0014240.g006
A20 in Diabetic Vasculopathy
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14240conditions that favor protein O-GlcNAcylation likely stems from
Sp1’s own O-GlcNAcylation, which hinders its ubiquitin-inde-
pendent, proteasomal degradation[44,45,46]. Further studies are
required to determine whether opposite effects of O-GlcNAcyla-
tion on Sp1 and A20 in terms of promoting/inhibiting
proteasomal degradation may relate to the ubiquitin-dependent
(A20) versus independent (Sp1) proteasomal degradation of these
proteins.
A more generalized defect in proteasome function as a result of
O-GlcNAcylation of the Rpt2 protein on the 19S cap proteasome
has also been proposed as a potential mechanism causing
decreased proteasomal degradation of Sp1 in high glucose
Figure 7. Expression of A20 in the ascending aorta and aortic arch of diabetic ApoE-null mice prevents the development of
atherosclerotic lesions by inhibiting PKCbII phosphorylation and blunting the induction of RAGE. (A) Transgene expression was
confirmed by X-gal staining in rAd.bgal-transduced vessels 5 days following transgene delivery (n=3 mice/group) and demonstrate the expression of
the transgene in medial SMC (M) as well as the adventitia at the level of the aortic root, albeit not in all cells. Image amplification 1006and 4006. (B)
A20 expression was verified by real time RT-PCR in two rAd.A20-transduced vessels, using human A20 specific primers that do not recognize mouse
A20. Our data indicate significant expression of human A20 in aortic roots of rAd.A20 but not saline treated mice. Results are shown as average6 SE.
(C) H&E stained aortic root sections at the level of the first coronary from 20 week-old diabetic ApoE-null mice treated with saline, rAd.A20 or
rAd.bgal. Images are shown at 1006and 4006as indicated by the scale bar. The asterisk indicates the level of the first coronary branch, Arrows
define the intima (I) and the media (M). ApoE-competent, non-diabetic C57BL/6 and non-diabetic ApoE-null mice were used as controls. Blood
glucose and cholesterol levels (cholest) are listed below the sections. *P,0.05 compared to saline, ** P,0.01 compared to rAd. bGal. Data shown are
representative of 4 to 6 mice per group. I/M ratios were calculated after analysis of 10 serial sections per vessel. (D) phospho-(p)PKCbII (5 days) and
RAGE (14 days) immunostaining in aortic arches 5 and 14 days after transgene delivery. Data shown in C are representative of all sections analyzed
(n=3 mice per group, 2–3 sections analyzed per vessel). Image amplification 2006.
doi:10.1371/journal.pone.0014240.g007
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O-GlcNAcylation on proteasome function in EC and SMC, we
demonstrated increased proteasomal degradation of A20 in these
cells when cultured in high glucose. This data does not support the
presence of a major defect in proteasome function in our system,
unlike those of NRK and breast cancer cell line MDA 468 [45].
While we recognize that we cannot rule out proteasome
dysfunction in EC and SMC cultured in high glucose, we
excluded a level of dysfunction that would significantly decrease
the degradation of ubiquitinated proteins, such as A20. Impor-
tantly, our results were validated in animal vessels and in patients’
vein graft samples.
Protein phosphorylation is another PTM that interacts with O-
GlcNAcylation, competing for the same residues to regulate
protein function [47]. Our data failed to demonstrate any effect of
high glucose upon phosphorylation of Ser381 a residue required
for A20’s NF-kB inhibitory function [30].
It is well established that hyperglycemia results in O-GlcNAc
mediated PTM that alters the expression/function of atheropro-
tective proteins, accelerating the development and progression of
DV [48]. O-GlcNAcylation of the atheroprotective protein eNOS
interferes with its phosphorylation by AKT, blunting its activity
and decreasing NO bioavailability [13,14]. Also, increased O-
GlcNAcylation of Sp1 decreases its degradation thereby increasing
transcription of the pro-atherogenic gene MCP-1 [40]. We present
novel evidence that the anti-inflammatory and atheroprotective
A20 protein is another target for O-GlcNAcylation and have yet to
demonstrate whether this PTM is a marker or a prerequisite for
the increased degradation of A20 in high glucose/hyperglycemia.
Our data are particularly interesting in light of a tag
polymorphism identified in the human A20 locus, in which minor
alleles were associated with lower A20 mRNA and 3-fold
increased incidence of coronary artery disease in well controlled
type II diabetics[49]. Patients with poor glycemic control showed
similar incidence of coronary artery disease regardless of A20
polymorphism. This apparent discrepancy is easily clarified by our
results demonstrating that high glucose/hyperglycemia induces the
degradation of the A20 protein, nullifying its atheroprotective
effects despite adequate mRNA transcription.
Under conditions that allow the accumulation of A20 in the
vasculature, this protein protects from DV by inhibiting the
damaging signals triggered by high glucose, namely RAGE
upregulation and PKCbII phosphorylation. In SMC challenged by
high glucose, we showed a remarkable reciprocal correlation between
RAGE and A20 expression. This is consistent with RAGE being a
NF-kB-dependent gene whose expression is induced by high glucose-
mediated activation of NF-kB [50]. Accordingly, RAGE upregula-
tion was amplified when the levels of the NF-kB inhibitory protein
A20 were decreased in cells exposed to high glucose [51], while
RAGE induction by high glucose/cytokines was inhibited upon
restoring A20 levels, either by rAd-mediated overexpression or by
inhibiting proteasome activity. A20 also inhibited the phosphoryla-
tion of PKCbII, which is preferentially activated in the vasculature of
diabetic animals [52]. Decreased A20 levels in vessels of diabetic
patients may account for the amplified and prolonged PKCbII
activation demonstrated in DM. We are investigating the molecular
basis for inhibition of PKCbII phosphorylation by A20.
Blockade of RAGE by soluble RAGE or treatment with
PKCbantagonists reduces macro and microvascular complications
of DM [33,53]. Therefore, it is not surprising that overexpression
of A20, which attenuated both RAGE expression and PKCbII
activation in aortic arches of diabetic ApoE-null mice, protected
from accelerated atherosclerosis despite persistent hyperglycemia
and aggravated dyslipidemia. While phospho-PKCbII is patho-
gnomonic for glucose-mediated vascular damage, increased
RAGE immunoreactivity was also detected in atherosclerotic
lesions of non-diabetic ApoE-null mice, consistent with increased
AGE/RAGE levels in response to the oxidative stress of
dyslipidemia [32,54]. This may account for the dramatic
atheroprotection provided by A20 in the diabetic ApoE-null
mouse model via down-regulation of hyperglycemia-dependent
and hyperglycemia-independent effectors of atherosclerosis.
From a basic science standpoint, these data propose a novel
mechanism by which O-GlcNAcylation promotes ubiquitination
and proteasomal degradation of A20 (Figure 9). Clinically, our
results identify the loss of the anti-inflammatory and atheropro-
tective protein A20 in DM as a key pathogenic contributor to DV,
given the protective effects of this protein against the deleterious
signals of high glucose in the vasculature [55,56] (Figure 9). From
a therapeutic standpoint, our data offer convincing proof that A20
or possibly GlcNAc-resistant A20-based gene therapy delivered to
the vessel wall may have clinical applicability in post-angioplasty
restenosis, and for modification of vein grafts for coronary artery
and peripheral bypass surgery.
Methods
Ethics Statement
The ethical committee of the Beth Israel Deaconess Medical
Center approved all experimental projects. All animal use is in
compliance with all current US government regulations concern-
Figure 8. Intravenous administration of rAd.A20 to diabetic
ApoE-null mice fails to protect them from accelerated athero-
sclerosis. Evaluation of I/M ratio on H&E stained aortic arch sections
from 20-week old mice (8 weeks following intravenous administration
of 2.5610
9 pfu/mice of rAd.A20 or saline) demonstrated comparable
intimal lesions in saline and rAd.A20-treated mice (n=6 mice/group).
Images are shown at the level of the first coronary artery at 1006
magnification. The asterisk indicates the level of the first coronary artery
branch. Arrows define the intima (I). Immunohistochemistry analysis of
RAGE and phospho-PKCbII (pPKCbII) demonstrate equally intense
staining in the neointima of saline and rAd.A20-treated mice. Image
amplification 4006.
doi:10.1371/journal.pone.0014240.g008
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veterinary concerns related to the use of mice as performed in this
paper. Supervision of animal care was conducted by staff members
of a fully AAALAC accredited facility headed by Dr. Garibaldi. All
personnel handling the animals followed a specialized training
prior to starting. The BIDMC has been certified for Animal
Welfare Assurance. The number is A3153-01, expiring on 2/28/
2014. The approved protocol number is #091-2006.
As for the discarded vein grafts from patients, the recovery of this
material follows all recent NIH/ADAHMA policy guidelines
concerning the inclusion of women and minorities in human research.
Recovery of vessels from patients in the operating room was approved
by the Institutional Review Board of the BIDMC. This study has been
approved by CCI with waiver of Consent and Authorization. These
tissues, which are otherwise discarded, were strictly used for research
purpose. The IRB approval number for this protocol is 2001-P-
002020/7; BIDMC Legacy #: W-91-0012-EX. The BIDMC holds a
Federal-Wide Assurance for human subjects: FWA00003245.
Reagents
Human coronary artery EC and SMC were obtained from
Lonza (Portsmouth, NH) [18,20]. Human recombinant TNF was
purchased from R&D Systems (Minneapolis, MN). The protea-
some inhibitor MG132, O-diazoacetyl-L-serine (Azaserine), a
glutamine analog that inhibits GFAT, and the GFAT inhibitor 6-
diazo-5-oxo-norleucine (DON) were from Sigma (St Louis, MO).
Recombinant adenoviral vectors
We generated a recombinant adenovirus encoding A20
(rAd.A20) from an expression plasmid (gift from Dr. V. Dixit,
Genentech Inc., CA). Control rAd. b-galactosidase (rAd.b gal) was
a gift from Dr. R. Gerard (University of Texas SW). SMC and EC
were transduced at a multiplicity of infection (MOI) of 500 and
100, as described [18,20].
Immunoprecipitation and Western blot
Immunoprecipitation (IP) was performed with homemade
rabbit anti-A20 polyserum or with agarose bound wheat germ
agglutinin (WGA, Vector laboratories, Burlingame CA) on spin-X
columns. Western blot (WB) analysis utilized rabbit anti-A20
polyserum as well as antibodies against the following: human A20,
RAGE and N-Acetylglucosamine (RL-2) (AbCam, Cambridge,
MA), phospho-A20 (gift of Dr. L. Cantley, BIDMC), phospho-
PKCbII Serine-660 (BioSource International, Camarillo, CA),
total (c-) PKCbII and bactin (Santa Cruz, Biotechnology, Santa
Cruz, CA), ubiquitin C-terminal Hydrolase, and GAPDH
(Chemicon International Inc. Temecular, CA). After scanning of
all films, densitometry of the bands of interest and of the
corresponding house keeping gene was performed using the
ImageJ software. In brief, the image was first inverted then an
exact markdown of the white bands was performed using the
hand-drawing tool The mean intensity of the delineated area was
measured, then corrected by the main intensity of the correspond-
ing house keeping gene band. Fold induction was determined
using the basal condition sample as one (1).
Real-time RT-PCR
RNA was extracted using RNeasy Mini Kits (Qiagen, Valencia,
CA) and cDNA synthesized using Superscript III First-Strand
Synthesis System (Invitrogen, Carlsbad, CA). Probes and primers
for human and mouse A20 were commercially purchased (Assays
on demand, Applied Biosystems Assays-on-demand Inc., Foster
City, CA). Expression of A20 mRNA was normalized to
expression of 18S rRNA.
Determination of glycosylation
SMC were harvested by sonication in lysis buffer comprising
5 mM HEPES pH 7.4, 10 mM NaCl, 0.1 mM DTT, 0.5 mM
EDTA, 5% glycerol supplemented with a protease inhibitor
cocktail (Roche Diagnostics Corporation, USA). Glycosylation was
determined by immunoprecipitation with agarose bound wheat
germ agglutinin (WGA, Vector laboratories, Burlingame CA) on
spin-X columns followed by WB analysis using rabbit anti-A20
polyclonal antibody[57].
RNA and protein extraction from mice aortae and
patients vein grafts
C57BL/6 and FVB/N mice were rendered diabetic by treatment
with five daily IP injections of streptozotocin (STZ, 60 mg/kg, Sigma)
in citrate buffer (0.05 M; pH 4.5). Control mice received citrate buffer.
STZ-treated mice with blood glucose .350 mg/dl at two consecutive
readings were considered diabetic. LPS (50 mg/mouse, Sigma) was
administered IP and the aortae were harvested 3 and 8 h later for
RNA (RLT lysis buffer) and protein (RIPA buffer supplemented with
protease inhibitors) extraction. Failed vein grafts from patients were
recovered from discarded tissue at the time of surgery, as approved by
the BIDMC Institutional Review Board (IRB), with waiver of Consent
and Authorization. These tissues, which are otherwise discarded, were
processed for RNA and protein extraction.
Accelerated atherosclerosis in diabetic ApoE-null mice
Male homozygous ApoE-null mice on the C57BL/6 back-
ground (Jackson Laboratories, Bar Harbor, ME) were maintained
Figure 9. High glucose promotes A20 O-glycosylation, ubiqui-
tination and proteasomal degradation in EC and SMC. High
glucose increases protein O-GlcNAcylation, including that of A20 and
possibly other E3 Ubiquitin ligases. This leads to increased A20
ubiquitination either through auto-ubiquitination or increased activity
of other O-GlcNAcylated E3 ubiquitin ligases. This targets A20 for
degradation in the proteasome. Blockade of O-GlcNAcylation using
DON, upstream of A20 Ubiquitination, or inhibition of proteasome
activity, using MG132, downstream of A20 ubiquitination would inhibit
its proteasomal degradation, restoring its expected protein levels.
doi:10.1371/journal.pone.0014240.g009
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diabetic with STZ. At 12 weeks of age, 5610
9 plaque forming
units (pfu) of rAd or saline were injected into the left ventricle of
anesthetized animals. Mice treated with similar dose and schedule,
but using the intravenous route, were included in the study to rule
out a systemic effect of the transgene on disease incidence. Eight
weeks after administration of the rAd, hearts and aortae were
removed ‘‘en bloc’’ following perfusion fixation in 10% formalin.
Serum cholesterol levels were measured at Cornell University
Diagnostic Laboratory (Ithaca, NY). Aortic arches were also
retrieved at day 0, 5, and 14 after adenoviral delivery and snap
frozen in Tissue-Tek. The BIDMC Institutional Animal Care and
Use Committee approved all procedures.
Histology and immunohistochemistry
As stated earlier the heart and the aortic arch were removed en
bloc… Paraffin embedded tissue sections were sectioned serially in
50 mM increments starting from the apex of the heart, and stained
with hematoxylin/eosin (H&E). Intima/media (I/M) ratios were
measured in a blinded fashion by 2 investigators (GVS and RP) on
10 consecutive serial section/sample, using ImageJ 1.62 software.
Lesions were demonstrated throughout the ascending aorta
starting at the beginning of the aortic root i.e the aortic annulus
and extending to the sinotubular junction. All images shown were
taken at the level of the first coronary artery. Frozen sections were
fixed with 2% paraformaldehyde (for RAGE) or acetone (for
phospho-PKCbII) prior to immunostaining and processing as
described [18]. b-galactosidase expression was detected by X-gal
staining. Immunohistochemistry (IHC) sections were analyzed by
EC, OK and CF.
Statistical Analysis
Quantitative data were expressed as mean6standard error of
mean (SEM). Statistical analysis was performed using analysis of
variance (ANOVA) followed by Tukey-Kramer multiple compar-
isons test or unpaired two-tailed student-t-test using GraphPad
InStat software. Some data were Natural Log transformed prior to
analysis. P,0.05 was considered to be statistically significant.
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